The Centers for Medicare & Medicaid Services Friday finalized policy and technical changes to the Medicare Advantage and prescription drug benefit for contract year 2023. To improve MA plan oversight, the final rule would reinstate plan reporting on medical loss ratio requirements that were relaxed in 2017; require plans to demonstrate a sufficient provider network when applying for a new or expanded contract; strengthen CMS’s ability to evaluate plan performance when reviewing proposals for new or expanded contracts; require plans to provide certain materials to beneficiaries in culturally and linguistically appropriate ways; and strengthen oversight of third-party marketing organizations, among other consumer protection provisions. The rule also codifies provisions intended to improve and better assess quality for special needs plans that serve beneficiaries dually eligible for Medicare and Medicaid. 

Related News Articles

Headline
The AHA today participated in a panel discussion during a conference hosted by The Capitol Forum on the impact of insurer vertical integration. Molly Smith,…
Headline
The Department of Health and Human Services Office of Inspector General yesterday issued an alert warning of marketing schemes by certain Medicare Advantage…
Headline
An analysis by KFF released last week found that in 2022, Medicare spent 27% ($2,585) more, on average, for individuals covered by Traditional Medicare after…
Headline
The Centers for Medicare & Medicaid Services Nov. 26 proposed changes to the Medicare Advantage and prescription drug programs for contract year 2026.…
Headline
The AHA Nov. 11 voiced strong support for the Centers for Medicare & Medicaid Services’ proposed plan for data collection and reporting requirements for…
Headline
A report released OCt. 23 by Kodiak Solutions found that Medicare Advantage plans classified three to four times as many hospital stays as observation visits…